Literature DB >> 3013274

HTLV-III antibody and T-cell subset ratios in haemophiliacs and their spouses.

B A McVerry, S J Machin, M J Galloway, K McCarthy, P Evans, R M Barnes, G C Turner, R Cheingsong-Popov, R S Tedder, M Winter.   

Abstract

44% of 63 British patients with either haemophilia A or B were HTLV-III antibody positive (HTLV-VIII+). HTLV-III+ was more frequent in high factor VIII concentrate users and 75% of severely affected haemophilia A patients were HTLV-III+. All eight patients who were exposed to factor IX concentrate were HTLV-III-. 17 haemophilia A patients who received only British made factor VIII concentrate (average 12,000 units/year) were HTLV-III-. Two of 63 patients had evidence of a pre-AIDS type symptom complex and both were HTLV-III+. Information from a cohort of 21 Liverpool haemophiliacs suggests that HTLV-III was first introduced into this country in 1981. OKT4/T8 ratios were abnormal in 52% of 21 patients studied but this finding was not confined to either HTLV-III+ or HTLV-III- individuals. The spouses of 14 HTLV-III+ haemophiliacs were all HTLV-III-.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013274     DOI: 10.1111/j.1365-2141.1986.tb05558.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Sexual transmission of HIV: routes, efficiency, cofactors and prevention. A survey of the literature.

Authors:  M van der Graaf; R Diepersloot
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

2.  Heterosexual transmission of HIV in hemophiliacs.

Authors:  T Kamradt; D Niese; H H Brackmann; K E Schneweis; B Kamps; B van Loo; P Euler
Journal:  Klin Wochenschr       Date:  1990-12-17

3.  Male-to-female transmission of HIV in a cohort of hemophiliacs--frequency, risk factors and effect of sexual counseling.

Authors:  J K Rockstroh; S Ewig; T Bauer; G Lüchters; J Oldenburg; E Bailly; R Kaiser; K E Schneweis; H H Brackmann; H J Dengler
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.